Prodrug for tumor therapy
Scientists of the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-Molar range) as well as a selective tumor therapy through their prodrugs based on the Antibody Directed Enzyme Prodrug Therapy (ADEPT). Selective is achieved by the specific tumor targeting through the antibody. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site through the enzyme, which is coupled to the antibody. While prodrugs have a low cytotoxicity, active drugs show an unbelievable cytotoxicity in the pico-molar range, much higher than actually used Doxorubicin. The drugs could be used equivalent to current chemotherapeutic agents or combined with e.g. a targeting-antibody.
We are now looking for companies, which are interested in licensing, developing and commercializing our approach.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-152
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
How evolution has optimised the magnetic sensor in birds
The magnetic sense of migratory birds is probably based on the protein cryptochrome 4, and a genetic study has now provided further support for this theory. A team of researchers…
Molecular Fingerprint Beyond the Nyquist Frequency
Ultrafast laser spectroscopy allows the ascertainment of dynamics over extremely short time scales, making it a very useful tool in many scientific and industrial applications. A major disadvantage is the…
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
